Chinese Academy of Sciences
cas.cnTotal trials
64
Active
11
Phase 3
6
Total enrollment
34,309,972
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| semaglutide | — | — | — | — | — | 2 | |
| Anti-GPC3-IRDye800CW | — | — | — | — | — | 1 | |
| Neoadjuvant Chemotherapy | — | — | — | — | — | 1 |
Next readouts
- 2024-08-31
- 2025-12-31
- 2026-12-30
- 2026-12-31
Top conditions
- Obesity6
- Spinal Cord Injury4
- Healthy4
- Vitamin D Deficiency3
- Weight Loss3
- Breast Cancer3
- Metabolic Syndrome X3
- Primary Ovarian Insufficiency2
Frequently asked questions about Chinese Academy of Sciences
- How many clinical trials does Chinese Academy of Sciences have on ClinicalTrials.gov?
- Chinese Academy of Sciences is listed as the lead sponsor on 64 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chinese Academy of Sciences's trials are in Phase 3?
- 6 of Chinese Academy of Sciences's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Chinese Academy of Sciences focus on?
- Chinese Academy of Sciences's most-studied conditions on ClinicalTrials.gov are Obesity, Spinal Cord Injury, Healthy, Vitamin D Deficiency, Weight Loss.
- When are Chinese Academy of Sciences's next clinical trial readouts?
- Chinese Academy of Sciences has 4 upcoming primary-completion readouts tracked here; the soonest is “AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy”, expected around 2024-08-31.